Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care

INTRODUCTION: Cost-effectiveness data on chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory large B cell lymphoma (R/R LBCL), accounting for inpatient/outpatient site of care (site), are sparse. METHODS: This payer model compares lifetime costs/benefits for CAR T cell-treated (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings Joyner, Alice Kate, Snider, Julia Thornton, Wade, Sally West, Wang, Si-Tien, Buessing, Marric G., Johnson, Scott, Gergis, Usama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309131/
https://www.ncbi.nlm.nih.gov/pubmed/35689726
http://dx.doi.org/10.1007/s12325-022-02188-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309131/
https://www.ncbi.nlm.nih.gov/pubmed/35689726
http://dx.doi.org/10.1007/s12325-022-02188-0

Ejemplares similares